Pharma companies settle bowel disease drug dispute
Pharmaceutical companies from Canada and Italy have agreed to settle a US$365 million ICC dispute over the development of a drug used in the treatment of inflammatory bowel disease.
To read more
Subscribe to Global Arbitration Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10